Semaglutide prescribing at medspa requires a licensed prescriber and a valid patient relationship—but state law, compounding status, and the good-faith exam create real operational constraints.
A medspa cannot prescribe semaglutide unless it employs or contracts a licensed prescriber—a physician, nurse practitioner, or physician assistant with prescriptive authority under state law. The medspa itself, as a business entity, has no prescribing power. The prescriber must establish a bona fide doctor-patient relationship, including a good-faith exam, before writing any prescription. This is non-negotiable under federal law and state medical boards.
Who Can Legally Prescribe
Semaglutide is a GLP-1 receptor agonist, FDA-approved for diabetes (Ozempic, Rybelsus) and weight loss (Wegovy, Saxenda). Only licensed prescribers can issue it:
- Physicians (MDs/DOs) — full prescriptive authority in all states
- Nurse practitioners (NPs) — prescriptive authority varies by state; some require physician supervision or collaborative agreements, others allow independent practice
- Physician assistants (PAs) — prescriptive authority varies; most require physician supervision
- Dentists, aestheticians, nurses without advanced licensure — cannot prescribe semaglutide under any circumstance
The prescriber must hold an active, unrestricted license in the state where the patient resides or where the prescription is issued, depending on state telehealth rules.
The Good-Faith Exam Requirement
Federal law and state medical boards require a good-faith medical exam before any prescription. This is not a checkbox; it is a documented clinical encounter—in-person or via synchronous telehealth—where the prescriber:
- Takes a relevant medical history (weight, BMI, comorbidities, prior weight-loss attempts, contraindications)
- Assesses cardiovascular risk, renal function, and medication interactions
- Documents the clinical rationale for semaglutide (diabetes management or weight loss in an appropriate candidate)
- Obtains informed consent regarding side effects, cost, and off-label use (if applicable)
A medspa that arranges semaglutide prescriptions without this documented exam—or that uses a prescriber who does not perform it—exposes itself to state medical board complaints, DEA scrutiny, and potential fraud allegations. Many state boards have explicitly cautioned against "telehealth mills" that issue semaglutide without genuine clinical evaluation.
Compounding and FDA Status
Semaglutide is a biologic (recombinant human GLP-1 analog). The FDA has not approved compounded semaglutide for any indication. Compounding pharmacies that prepare semaglutide from bulk powder or other sources operate in a regulatory gray zone:
Compounded semaglutide is not FDA-approved; a prescriber who writes for it assumes liability that most medspa operators cannot afford.
- Compounded semaglutide is not FDA-approved and carries no guarantee of sterility, potency, or purity
- The FDA has issued warning letters to compounding facilities and has stated that compounding semaglutide without an FDA-approved reference product is not permitted under standard compounding rules
- A prescriber who writes for compounded semaglutide assumes liability for adverse events and may face board discipline
Many medspa operators are drawn to compounded semaglutide because it costs less than branded Ozempic or Wegovy. However, the legal and clinical risk is substantial. A prescriber should dispense only FDA-approved semaglutide (Ozempic, Wegovy, Rybelsus, Saxenda) or refer the patient to a pharmacy that fills an FDA-approved product.
State-by-State Variation
Prescriptive authority for NPs and PAs differs markedly:
- Full independent practice states (California, New York, Florida, Texas, and others) — NPs with appropriate training can prescribe semaglutide without physician oversight
- Collaborative/supervisory states — NPs and PAs must work under a physician's supervision or collaborative agreement; the supervising physician may need to co-sign or review prescriptions
- Restrictive states — some states limit NP/PA prescribing to specific drug classes or require physician presence
A medspa operating across multiple states must verify the prescriptive scope in each jurisdiction. Telemedicine adds complexity: if a medspa in State A arranges a telehealth visit with a prescriber in State B to treat a patient in State C, the prescriber must be licensed in State C (or comply with that state's telehealth reciprocity rules).
Practical Compliance for Medspa Owners
If your medspa wants to offer semaglutide:
- Hire or contract a licensed prescriber with active state licensure and malpractice insurance
- Document the good-faith exam in the patient's medical record (date, findings, clinical indication, informed consent)
- Dispense only FDA-approved products through a licensed pharmacy or direct dispensary (where permitted)
- Verify state scope-of-practice rules for your prescriber (NP vs. PA vs. MD, supervision requirements)
- Obtain informed consent that includes cost, side effects, and the fact that semaglutide is being used off-label if prescribed for weight loss in a non-diabetic patient
- Maintain malpractice coverage that includes prescribing and injection services
Semaglutide is a high-margin service for medspas, but it is also a high-risk one. Cutting corners on the prescriber relationship, the exam, or the product source invites regulatory action and patient harm.
Frequently asked questions
Can a medspa prescribe semaglutide?
No, a medspa as a business entity cannot prescribe semaglutide. Only a licensed prescriber—physician, nurse practitioner, or physician assistant with prescriptive authority—employed or contracted by the medspa can issue the prescription. The prescriber must hold an active, unrestricted license in the state where the patient resides or where the prescription is issued.
What is required before a medspa can dispense semaglutide?
A licensed prescriber must conduct a documented good-faith medical exam—in-person or via synchronous telehealth—that includes medical history, cardiovascular and renal assessment, and clinical rationale for semaglutide. This exam is required by federal law and state medical boards; medspa operators who arrange prescriptions without this documented evaluation face medical board complaints, DEA scrutiny, and fraud allegations.
Can a medspa use compounded semaglutide?
No. The FDA has not approved compounded semaglutide and has issued warning letters to compounding facilities preparing it from bulk powder. A prescriber who writes for compounded semaglutide assumes full liability for adverse events and risks state board discipline. Medspa operators should dispense only FDA-approved products (Ozempic, Wegovy, Rybelsus, Saxenda) or refer patients to a pharmacy filling an approved product.
Can a nurse practitioner or physician assistant prescribe semaglutide at a medspa?
Yes, if they hold prescriptive authority in their state. However, prescriptive authority for NPs and PAs varies significantly by state—some require physician supervision or collaborative agreements, while others allow independent practice. The prescriber must verify their state's specific requirements before issuing any semaglutide prescription.
Who cannot prescribe semaglutide at a medspa?
Dentists, aestheticians, registered nurses without advanced licensure, and other non-prescribing staff cannot prescribe semaglutide under any circumstance. Only physicians (MDs/DOs), nurse practitioners, and physician assistants with active, unrestricted licenses and prescriptive authority in their state are legally permitted to issue semaglutide prescriptions.
What happens if a medspa prescribes semaglutide without a good-faith exam?
The medspa and prescriber face state medical board complaints, potential DEA scrutiny, and fraud allegations. Many state boards have explicitly cautioned against telehealth mills that issue semaglutide without genuine clinical evaluation. The documented exam—including medical history, cardiovascular assessment, and clinical rationale—is non-negotiable under federal law and state regulations.
Free weekly brief Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
